Yeeun Seo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yeeun Seo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Hokyou Lee
Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea
5 shared publications - Hyeon Chang Kim
Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea
5 shared publications - Eunji Kim
Department of Preventive Medicine, Gachon University College of Medicine , Incheon
4 shared publications - Hyeok-Hee Lee
Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
4 shared publications - Jenny Moon
Department of Public Health, Yonsei University Graduate School, Seoul, Korea
3 shared publications - Sojung Shin
Department of Public Health, Yonsei University Graduate School, Seoul, Korea
3 shared publications
Latest Publications
- 25 March 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Cardiovascular health by Life’s Essential 8 and chronic kidney disease: Korea National Health and Nutrition Examination Survey 2019–2021
Evidence remains limited regarding the association between cardiovascular health (CVH), as defined by Life's Essential 8 (LE8), and chronic kidney disease (CKD), particularly across its indicators and stages. We analyzed data from 12,264 adults in the Korea National Health and Nutrition Examination Survey (2019-2021). LE8 scores (range, 0-100), calculated from eight components-diet, physical activity, nicotine exposure, sleep, body mass index, blood lipids, blood glucose, and blood pressure, were analyzed as both continuous and categorical variables: low (0 to <50), moderate (50 to <80), and high CVH (80 to 100). CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g). Multivariable logistic regression and restricted cubic spline models were used to examine associations between LE8 scores and CKD, with stratification by CKD indicators and by G and A stages. Overall, 13.3% of participants were classified as having low CVH, 75.4% as moderate CVH, and 11.3% as high CVH. Compared to low CVH, the odds of CKD were lower in moderate CVH (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.33-0.46) and high CVH (OR, 0.22; 95% CI, 0.15-0.33). Each 10-point higher CVH score was associated with 33% lower odds of CKD (OR, 0.67; 95% CI, 0.63-0.71). After stratifying decreased eGFR and albuminuria by G and A stages, higher CVH was consistently associated with lower odds of CKD, even for early stages. Higher LE8 scores were inversely associated with CKD and its indicators, including early-stage CKD.
- 25 March 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Cardiovascular health by Life’s Essential 8 and chronic kidney disease: Korea National Health and Nutrition Examination Survey 2019–2021
Evidence remains limited regarding the association between cardiovascular health (CVH), as defined by Life's Essential 8 (LE8), and chronic kidney disease (CKD), particularly across its indicators and stages. We analyzed data from 12,264 adults in the Korea National Health and Nutrition Examination Survey (2019-2021). LE8 scores (range, 0-100), calculated from eight components-diet, physical activity, nicotine exposure, sleep, body mass index, blood lipids, blood glucose, and blood pressure, were analyzed as both continuous and categorical variables: low (0 to <50), moderate (50 to <80), and high CVH (80 to 100). CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g). Multivariable logistic regression and restricted cubic spline models were used to examine associations between LE8 scores and CKD, with stratification by CKD indicators and by G and A stages. Overall, 13.3% of participants were classified as having low CVH, 75.4% as moderate CVH, and 11.3% as high CVH. Compared to low CVH, the odds of CKD were lower in moderate CVH (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.33-0.46) and high CVH (OR, 0.22; 95% CI, 0.15-0.33). Each 10-point higher CVH score was associated with 33% lower odds of CKD (OR, 0.67; 95% CI, 0.63-0.71). After stratifying decreased eGFR and albuminuria by G and A stages, higher CVH was consistently associated with lower odds of CKD, even for early stages. Higher LE8 scores were inversely associated with CKD and its indicators, including early-stage CKD.
- Top Cited PapersOpen Access
- 1 January 2024
- Published by XMLink in Clinical Hypertension
- Vol. 30 (1) , 1-11
Korea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations
The Korea Hypertension Fact Sheet 2023, presented by the Korean Society of Hypertension, offers an overview of the prevalence and management of hypertension, along with recent trends. Data for the Fact Sheet were derived from the Korea National Health and Nutrition Examination Survey spanning 1998 to 2021, and the National Health Insurance Big Data from 2002 to 2021. As of 2021, hypertension affected 28.0% of Korean adults aged 20 and older, totaling approximately 12.3 million individuals, with 5.3 million (43.5%) aged 65 or older. Among those with hypertension, awareness stood at 74.1%, treatment rates at 70.3%, and control rates at 56.0%. Over the years, the number of hypertension diagnoses increased from 3.0 million in 2002 to 11.1 million in 2021. During the same period, the utilization of antihypertensive medications rose from 2.5 million to 10.5 million, with treatment adherence also improving from 0.6 million to 7.8 million individuals. In 2021, the predominant antihypertensive drug class was angiotensin receptor blockers (75.1%), followed by calcium channel blockers (61.7%), diuretics (23.4%), and beta blockers (15.3%). Notably, 60.2% of all antihypertensive prescriptions involved combination therapy with at least two classes of antihypertensive medication. There was a positive trend towards stricter blood pressure control targets (systolic/diastolic blood pressure < 130/80 mmHg) among elderly hypertensive patients, as well as those with diabetes, obesity, and high-risk hypertension. However, this trend declined in individuals aged 80 years or older and those with chronic kidney disease in recent years. In Korea, hypertension management is making strides, yet the total number of hypertensive individuals is rising. Effectively addressing the growing population of elderly hypertensive patients and the persistently low treatment rates among younger individuals with hypertension is a critical challenge. Additionally, developing more efficient and customized policies for blood pressure control and cardiovascular disease prevention is imperative.
- 1 January 2024
- Published by XMLink in Clinical Hypertension
- Vol. 30 (1) , 1-11
Top Cited PapersOpen AccessKorea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations
The Korea Hypertension Fact Sheet 2023, presented by the Korean Society of Hypertension, offers an overview of the prevalence and management of hypertension, along with recent trends. Data for the Fact Sheet were derived from the Korea National Health and Nutrition Examination Survey spanning 1998 to 2021, and the National Health Insurance Big Data from 2002 to 2021. As of 2021, hypertension affected 28.0% of Korean adults aged 20 and older, totaling approximately 12.3 million individuals, with 5.3 million (43.5%) aged 65 or older. Among those with hypertension, awareness stood at 74.1%, treatment rates at 70.3%, and control rates at 56.0%. Over the years, the number of hypertension diagnoses increased from 3.0 million in 2002 to 11.1 million in 2021. During the same period, the utilization of antihypertensive medications rose from 2.5 million to 10.5 million, with treatment adherence also improving from 0.6 million to 7.8 million individuals. In 2021, the predominant antihypertensive drug class was angiotensin receptor blockers (75.1%), followed by calcium channel blockers (61.7%), diuretics (23.4%), and beta blockers (15.3%). Notably, 60.2% of all antihypertensive prescriptions involved combination therapy with at least two classes of antihypertensive medication. There was a positive trend towards stricter blood pressure control targets (systolic/diastolic blood pressure < 130/80 mmHg) among elderly hypertensive patients, as well as those with diabetes, obesity, and high-risk hypertension. However, this trend declined in individuals aged 80 years or older and those with chronic kidney disease in recent years. In Korea, hypertension management is making strides, yet the total number of hypertensive individuals is rising. Effectively addressing the growing population of elderly hypertensive patients and the persistently low treatment rates among younger individuals with hypertension is a critical challenge. Additionally, developing more efficient and customized policies for blood pressure control and cardiovascular disease prevention is imperative.
- Open Access
- 26 December 2023
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 46, e2024003
Incidence and case fatality of stroke in Korea, 2011-2020
OBJECTIVES: Stroke remains the second leading cause of death in Korea. This study was designed to estimate the crude, age-adjusted and age-specific incidence rates, as well as the case fatality rate of stroke, in Korea from 2011 to 2020.METHODS: We utilized data from the National Health Insurance Services from January 1, 2002 to December 31, 2020, to calculate incidence rates and 30-day and 1-year case fatality rates of stroke. Additionally, we determined sex and age-specific incidence rates and computed age-standardized incidence rates by direct standardization to the 2005 population.RESULTS: The crude incidence rate of stroke hovered around 200 (per 100,000 person-years) from 2011 to 2015, then surged to 218.4 in 2019, before marginally declining to 208.0 in 2020. Conversely, the age-standardized incidence rate consistently decreased by 25% between 2011 and 2020. When stratified by sex, the crude incidence rate increased between 2011 and 2019 for both sexes, followed by a decrease in 2020. Age-standardized incidence rates displayed a downward trend throughout the study period for both sexes. Across all age groups, the 30-day and 1-year case fatality rates of stroke consistently decreased from 2011 to 2019, only to increase in 2020.CONCLUSIONS: Despite a decrease in the age-standardized incidence rate, the total number of stroke events in Korea continues to rise due to the rapidly aging population. Moreover, 2020 witnessed a decrease in incidence but an increase in case fatality rates.
- 26 December 2023
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 46, e2024003
Open AccessIncidence and case fatality of stroke in Korea, 2011-2020
OBJECTIVES: Stroke remains the second leading cause of death in Korea. This study was designed to estimate the crude, age-adjusted and age-specific incidence rates, as well as the case fatality rate of stroke, in Korea from 2011 to 2020.METHODS: We utilized data from the National Health Insurance Services from January 1, 2002 to December 31, 2020, to calculate incidence rates and 30-day and 1-year case fatality rates of stroke. Additionally, we determined sex and age-specific incidence rates and computed age-standardized incidence rates by direct standardization to the 2005 population.RESULTS: The crude incidence rate of stroke hovered around 200 (per 100,000 person-years) from 2011 to 2015, then surged to 218.4 in 2019, before marginally declining to 208.0 in 2020. Conversely, the age-standardized incidence rate consistently decreased by 25% between 2011 and 2020. When stratified by sex, the crude incidence rate increased between 2011 and 2019 for both sexes, followed by a decrease in 2020. Age-standardized incidence rates displayed a downward trend throughout the study period for both sexes. Across all age groups, the 30-day and 1-year case fatality rates of stroke consistently decreased from 2011 to 2019, only to increase in 2020.CONCLUSIONS: Despite a decrease in the age-standardized incidence rate, the total number of stroke events in Korea continues to rise due to the rapidly aging population. Moreover, 2020 witnessed a decrease in incidence but an increase in case fatality rates.
- Open Access
- 26 December 2023
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 46, e2024002
Incidence and case fatality of acute myocardial infarction in Korea, 2011-2020
OBJECTIVES: Cardiovascular diseases are a leading cause of mortality worldwide, and acute myocardial infarction (AMI) is particularly fatal condition. We evaluated the incidence and case fatality rates of AMI in Korea from 2011 to 2020.METHODS: We utilized data from the National Health Insurance Services to calculate crude, age-standardized, and age-specific incidence rates, along with 30-day and 1-year case fatality rates, of AMI from 2011 to 2020. Age-standardized incidence rates were determined using direct standardization to the 2005 population.RESULTS: The crude incidence rate of AMI per 100,000 person-years consistently increased from 44.7 in 2011 to 68.3 in 2019, before decreasing slightly to 66.2 in 2020. The age-standardized incidence rate of AMI displayed a 19% rise from 2011 to 2019, followed by a slight decline in 2020. The increasing trend for AMI incidence was more pronounced in males than in females. Both 30-day and 1-year case fatality rates remained stable among younger individuals but showed a decrease among older individuals. There was a minor surge in case fatality in 2020, particularly among recurrent AMI cases.CONCLUSIONS: Over the past decade, the AMI incidence rate in Korea has consistently increased, with a slight downturn in 2020. The case fatality rate has remained relatively stable except for a minor increase in 2020. This study provides data for continuous surveillance, the implementation of targeted interventions, and the advancement of research aimed at AMI in Korea.
- 26 December 2023
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 46, e2024002
Open AccessIncidence and case fatality of acute myocardial infarction in Korea, 2011-2020
OBJECTIVES: Cardiovascular diseases are a leading cause of mortality worldwide, and acute myocardial infarction (AMI) is particularly fatal condition. We evaluated the incidence and case fatality rates of AMI in Korea from 2011 to 2020.METHODS: We utilized data from the National Health Insurance Services to calculate crude, age-standardized, and age-specific incidence rates, along with 30-day and 1-year case fatality rates, of AMI from 2011 to 2020. Age-standardized incidence rates were determined using direct standardization to the 2005 population.RESULTS: The crude incidence rate of AMI per 100,000 person-years consistently increased from 44.7 in 2011 to 68.3 in 2019, before decreasing slightly to 66.2 in 2020. The age-standardized incidence rate of AMI displayed a 19% rise from 2011 to 2019, followed by a slight decline in 2020. The increasing trend for AMI incidence was more pronounced in males than in females. Both 30-day and 1-year case fatality rates remained stable among younger individuals but showed a decrease among older individuals. There was a minor surge in case fatality in 2020, particularly among recurrent AMI cases.CONCLUSIONS: Over the past decade, the AMI incidence rate in Korea has consistently increased, with a slight downturn in 2020. The case fatality rate has remained relatively stable except for a minor increase in 2020. This study provides data for continuous surveillance, the implementation of targeted interventions, and the advancement of research aimed at AMI in Korea.
- Open Access
- 1 January 2023
- Published by XMLink in Clinical Hypertension
- Vol. 29 (1) , 1-5
Korea hypertension fact sheet 2022: analysis of nationwide population-based data with a special focus on hypertension in the elderly
The Korean Society of Hypertension has published the Korea Hypertension Fact Sheet 2022 to provide an overview of the magnitude and management status of hypertension and their recent trends. The Fact Sheets were based on the analyses of Korean adults aged 20 years or older of the 1998–2020 Korea National Health and Nutrition Examination Survey and the 2002–2020 National Health Insurance Big Data. As of 2020, 29.4% of the adult population aged 20 or older in Korea, about 12.6 million people, have high blood pressure, of which 5.0 million (40%) are 65 years of age or older and 1.2 million (10%) are 80 years of age or older. Among those with hypertension, the awareness rate is 69%, the treatment rate is 65%, and the control rate is 47%. The number of people diagnosed with hypertension increased from 3.0 million in 2002 to 10.5 million in 2020. During the same period, the number of people using antihypertensive medication increased from 2.5 million to 9.9 million, and the number of people adherent to treatment increased from 0.6 million to 7.4 million. Among those treated for hypertension in 2020, 74% used angiotensin blockers, 61% used calcium channel blockers, 24% used diuretics, and 15% used beta blockers. Combination therapy with at least two classes of antihypertensive medication consisted of 60% of all antihypertensive prescriptions. The number of people with hypertension aged 65 or older is increasing very rapidly compared to those aged 20–64. Awareness and treatment rates of hypertension improved rapidly, especially in those aged 65 or older, but the rate of improvement slowed since 2012. In Korea, the level of hypertension management is improving, but the absolute number of people with hypertension, especially elderly hypertension, is increasing due to the rapid aging of the population. It is necessary to develop more efficient and target-specific policies to control blood pressure and prevent cardiovascular disease.
- 1 January 2023
- Published by XMLink in Clinical Hypertension
- Vol. 29 (1) , 1-5
Open AccessKorea hypertension fact sheet 2022: analysis of nationwide population-based data with a special focus on hypertension in the elderly
The Korean Society of Hypertension has published the Korea Hypertension Fact Sheet 2022 to provide an overview of the magnitude and management status of hypertension and their recent trends. The Fact Sheets were based on the analyses of Korean adults aged 20 years or older of the 1998–2020 Korea National Health and Nutrition Examination Survey and the 2002–2020 National Health Insurance Big Data. As of 2020, 29.4% of the adult population aged 20 or older in Korea, about 12.6 million people, have high blood pressure, of which 5.0 million (40%) are 65 years of age or older and 1.2 million (10%) are 80 years of age or older. Among those with hypertension, the awareness rate is 69%, the treatment rate is 65%, and the control rate is 47%. The number of people diagnosed with hypertension increased from 3.0 million in 2002 to 10.5 million in 2020. During the same period, the number of people using antihypertensive medication increased from 2.5 million to 9.9 million, and the number of people adherent to treatment increased from 0.6 million to 7.4 million. Among those treated for hypertension in 2020, 74% used angiotensin blockers, 61% used calcium channel blockers, 24% used diuretics, and 15% used beta blockers. Combination therapy with at least two classes of antihypertensive medication consisted of 60% of all antihypertensive prescriptions. The number of people with hypertension aged 65 or older is increasing very rapidly compared to those aged 20–64. Awareness and treatment rates of hypertension improved rapidly, especially in those aged 65 or older, but the rate of improvement slowed since 2012. In Korea, the level of hypertension management is improving, but the absolute number of people with hypertension, especially elderly hypertension, is increasing due to the rapid aging of the population. It is necessary to develop more efficient and target-specific policies to control blood pressure and prevent cardiovascular disease.